NPC1L1 and prostate carcinoma: Genetically proxied inhibition of NPC1L1 was associated with higher overall prostate cancer risk which likewise had a 95% CI that included the null (OR = 1.34, 95% CI = 0.87 to 2.04, P = 0.180).